Drug · DIN 02559226
OMVOH
SINGLE-USE PREFILLED SYRINGE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 22, 2025; first marketed October 22, 2025.
- Drug Identification Number (DIN)
- 02559226
- Company (DIN owner)
- Eli Lilly Canada IncToronto, Ontario, Canada
- Schedule
- Prescription; Schedule d
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Mirikizumab L04AC24
- Class
- Human
- Record last updated
- August 4, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| MIRIKIZUMAB | 200 ML | 2 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 8, 2025: NOC 36284Supplement to a New Drug Submission (SNDS) · 1. New formulation 2. New presentations 3. New indication: Omvoh is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic treatment
Other DINs named OMVOH
- DIN 02539845 · Marketed
- DIN 02539853 · Marketed
- DIN 02539861 · Marketed
- DIN 02559218 · Marketed
- DIN 02559234 · Marketed
- DIN 02559242 · Marketed